39 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Novartis Resubmits BLA to FDA for Biosimilar of Neulasta http://www.zacks.com/stock/news/370752/novartis-resubmits-bla-to-fda-for-biosimilar-of-neulasta?cid=CS-ZC-FT-370752 Apr 04, 2019 - Novartis' (NVS) generic arm Sandoz resubmits its BLA for the proposed biosimilar of Neulasta.
Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval http://www.zacks.com/stock/news/370846/pfizers-new-lung-cancer-drug-vizimpro-gets-eu-approval?cid=CS-ZC-FT-370846 Apr 04, 2019 - Pfizer's (PFE) new lung cancer medicine, Vizimpro (dacomitinib) gets approval in EU after being approved in the United States last September.
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again http://www.zacks.com/stock/news/371457/why-amgen-amgn-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-371457 Apr 05, 2019 - Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More http://www.zacks.com/stock/news/376834/biotech-stock-roundup-amgns-evenity-earns-fda-approval-deal-wins-more?cid=CS-ZC-FT-376834 Apr 10, 2019 - Key highlights of the past week are new drug approvals, collaborations and pipeline updates.
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group http://www.zacks.com/stock/news/379812/mercks-keytruda-gets-fda-nod-for-expanded-lung-cancer-group?cid=CS-ZC-FT-379812 Apr 12, 2019 - Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for http://www.zacks.com/stock/news/393228/analysts-estimate-amgen-amgn-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-393228 Apr 23, 2019 - Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novartis (NVS) Q1 Earnings Beat Estimates, Revenues Up Y/Y http://www.zacks.com/stock/news/394696/novartis-nvs-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-394696 Apr 24, 2019 - Novartis (NVS) beats on Q1 earnings, sales marginally miss estimates.
Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates? http://www.zacks.com/stock/news/398971/pfizer-pfe-to-report-q1-earnings-will-it-beat-estimates?cid=CS-ZC-FT-398971 Apr 24, 2019 - While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
Is a Beat in Store for Cigna (CI) This Earnings Season? http://www.zacks.com/stock/news/405319/is-a-beat-in-store-for-cigna-ci-this-earnings-season?cid=CS-ZC-FT-405319 Apr 29, 2019 - Cigna's (CI) Q1 earnings should benefit from increase in revenues and membership.
Amgen Inc (AMGN) Q1 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/04/30/amgen-inc-amgn-q1-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Apr 30, 2019 - AMGN earnings call for the period ending March 31, 2019.

Pages: 1234

Page 1>